About Kritika Sarmah

Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist. She earned her bachelor's degree in commerce and is currently pursuing the CFA program. With her fundamental approach, she aims to help investors identify untapped investment opportunities.


Recent Articles By Kritika Sarmah

: VWAGY |  News, Ratings, and Charts

Top 3 Value Auto Stock Buys for April

This year, the automotive industry is likely to accelerate with soaring electric vehicle sales and infrastructure advancements. Hence, quality auto stocks Bayerische Motoren Werke (BMWYY), Volkswagen (VWAGY), and REV Group (REVG), which boast lower-than-industry valuation multiples, might be solid buys for April. Keep reading...
: GOOGL |  News, Ratings, and Charts

Will GOOGL and AMZN Reign Supreme Among Tech Stocks in 2024?

Amidst the ever-changing digital terrain and the ascent of artificial intelligence (AI), the future looks promising for tech behemoths Alphabet (GOOGL) and Amazon.com (AMZN). Yet, a pressing query looms: Can GOOGL and AMZN uphold their status as reigning tech stock champions this year? Let's delve deeper to uncover the answer...
: BOX |  News, Ratings, and Charts

3 Top-Rated Tech Stock Buys for Value in April

The technology sector is undergoing a notable surge, propelled by increasing digitalization endeavors among businesses and governmental support for technological progress. So, fundamentally sound tech stocks Box Inc. (BOX), Teradata (TDC), and Materialise (MTLS), which seem pretty undervalued, might be ideal buys this month. Continue reading...
: GMAB |  News, Ratings, and Charts

3 Biotech Stocks Gaining Altitude and Interest

This year, the biotech industry anticipates a resurgence with increased M&A, FDA approvals, and AI-driven innovations. Given the industry’s rosy prospects, biotech stocks BioMarin Pharmaceutical (BMRN), ANI Pharmaceuticals (ANIP), and Genmab A/S (GMAB), gaining significant altitude and interest, could be ideal buys. Read on...
: ET |  News, Ratings, and Charts

3 Energy Stock Buys Surging Past Expectations

Rising oil prices due to escalating geopolitical tensions and supply concerns should bode well for the energy sector. So, I think fundamentally solid energy stocks Energy Transfer (ET), Pembina Pipeline (PBA), and Matrix Service (MTRX) might be ideal buys. Read more...
: NVO |  News, Ratings, and Charts

4 Pharma Giants Sparking Investor Interest

The pharmaceutical industry is growing steadily, focusing more on technological innovation, precision medicine, and strategic mergers and acquisitions (M&A). So, let’s take a look at pharma giants Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), Merck & Co. (MRK), and AbbVie (ABBV) igniting investor interest. Keep reading…
: BLK |  News, Ratings, and Charts

BlackRock (BLK) Pre-Earnings Outlook - Hold or Sell?

With $10 trillion in AUM and upcoming acquisitions, Investment Giant BlackRock’s (BLK) long-term prospects shine bright. However, macroeconomic challenges exist. As the company gears up to unveil its earnings this Friday, let us analyze whether the stock is a Hold or Sell…
: STZ |  News, Ratings, and Charts

Is Constellation Brands (STZ) Preparing for an Earnings Boost?

The prominent alcohol beverage company, Constellation Brands (STZ), is preparing to unveil its fiscal third-quarter earnings this week. While the alcohol beverage market is growing, intense competition may present challenges for STZ. Let's delve into its fundamentals to determine if the stock is primed for a surge this week…
: CAJPY |  News, Ratings, and Charts

3 Tech Stocks Set to Soar Beyond Expectations

The technology sector’s significant growth is fueled by continued technological innovation, Gen Z's mobile habits, and rising demand for versatile devices. Hence, it could be wise to invest in tech stocks Canon (CAJPY), Zoom Video Communications (ZM), and Brother Industries (BRTHY), which are poised to surpass expectations. Continue reading...
: NVO |  News, Ratings, and Charts

Canopy Growth (CGC) vs. Novo Nordisk (NVO): Which Pharma Stock Is a Better Investment?

The Pharma sector’s innovative trial methodologies and shift toward customized medicine signal transformative growth potential in the pharmaceutical industry. While leading Pharma stocks Canopy Growth (CGC) and Novo Nordisk (NVO) stand to benefit, let us analyze which of them is a better investment...
Page generated in 1.5573 seconds.